Medicaid, Section 340B, Trump Administration

Holland & Knight Health Dose: July 8, 2025

Holland & Knight LLP on 7/10/2025

With the reconciliation package signed into law, the U.S. House of Representatives is in recess and will return on July 14, 2025. In the interim, the U.S. Senate will focus on the appropriations bills for fiscal year (FY)...more

Healthcare Life Sciences Drug Pricing Digest - May 2025

Latham & Watkins LLP on 5/6/2025

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more

Healthcare Policy Options to Reduce the Deficit

McDermott+ on 1/24/2025

The Trump Administration and 119th Congress will likely be targeting trillions of dollars in savings in the year ahead. Healthcare makes up a significant portion of mandatory spending and therefore likely will be a large part...more

How the US Election May Affect Drug Pricing, Medicare, and Medicaid Programs – Key Areas to Watch

Morgan Lewis on 12/5/2024

Heading into the new year, a Trump-Vance administration will control the White House and the Republicans will hold a narrow majority in both the House and Senate. This control trifecta is likely to impact both legislative and...more

Uncertainty on Drug Pricing Remains Following Trump Administration Executive Orders

White & Case LLP on 8/1/2020

On July 24 2020, President Trump signed three Executive Orders targeting prescription drug prices and proposed a fourth. The Orders represent the Trump Administration's latest effort to implement previously outlined...more

Courts and Healthcare Policy in 2020

McGuireWoods Consulting on 1/15/2020

2019 saw court hearings of a number of cases related to the Affordable Care Act (ACA). Several other Trump administration policies were also challenged, including Medicare payment policies, price transparency, how the...more

K&L Gates Triage: Recent Developments Impacting Drug Pricing and the 340B Program: Part 1

K&L Gates LLP on 9/6/2019

In Part One of this two-part series on recent developments in pharmacy law and the 340B drug pricing program, Richard Church and Ryan Severson discuss several recent developments that may affect drug pricing and pharmacy...more

Congress Acts to Eliminate MDRP Misclassification

King & Spalding on 4/22/2019

President Trump on Thursday signed into law the most extensive set of amendments to the Medicaid Drug Rebate Program statute since the Affordable Care Act in 2010. The new law addresses the perception that drug manufacturers...more

President Trump's Budget: Key Takeaways for Health Care

Baker Donelson on 3/18/2019

President Trump's fiscal year 2020 (FY20) budget proposal for the Department of Health and Human Services (HHS) reflects the Trump Administration's priorities to repeal and replace the Affordable Care Act (ACA), implement...more

Washington Healthcare Update

McGuireWoods Consulting on 1/8/2019

This Week: Happy New Year! The 116th Congress begins and healthcare issues are part of the "buzz" of day one. Part of the government is still closed. ...more

Six Initiatives States May Pursue to Curb Drug Prices and the 340B Factor

Mintz - Health Care Viewpoints on 10/24/2018

For much of the past 18 months, the Trump Administration, and in particular CMS, have talked a good game regarding reducing pharmaceutical prices. On October 16, 2018, a key component of the Administration’s strategy was...more

Window On Washington - Vol. 2, Issue 37

Clark Hill PLC on 9/17/2018

Outlook for This Week in the Nation's Capital - Appropriations Update. The next minibus package vote will be on the Defense and Labor-HHs appropriations bills and could also include a continuing resolution for the...more

Administration Drug Pricing Proposals Could Reduce Provider Payments

Baker Donelson on 8/10/2018

As the Trump Administration moves forward with proposed policy changes to address high drug prices, a common theme is emerging: a number of the proposals have the potential to reduce Medicare reimbursement to hospitals and...more

July 2018: Where Are We Now With 340B?

Mintz - Health Care Viewpoints on 7/17/2018

It seems like every week, there are multiple new developments in the 340B program. While it has just been a few weeks since my last 340B blog post, since that time we have had another Senate hearing, a new GAO Report, a new...more

Health Care Weekly Preview from ML Strategies – July 2018

Mintz - Health Care Viewpoints on 7/11/2018

This week, Congress returns from recess to another four-week work period that will immediately become contentious. Tonight, President Trump is expected to make his Supreme Court pick this week. This could change the dynamics...more

Health Care Policy Newsletter - July 2018

Foley & Lardner LLP on 7/2/2018

Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more

A Deeper Dive: What the Trump Administration Blueprint to Lower Drug Prices Might Mean for Medicaid

Mintz - Health Care Viewpoints on 6/19/2018

It has been a few weeks since the publication of the Trump Administration’s Blueprint to Lower Drug Prices, and Secretary Azar’s Request for Information (RFI) on the Blueprint. We previously posted about the Blueprint’s focus...more

What's New In Washington - March 2018

Akin Gump Strauss Hauer & Feld LLP on 6/7/2018

Washington saw a flurry of bipartisan activity over the last few weeks. Most notably, Republican and Democratic negotiators reached a long-awaited deal on sequestration budget caps. The compromise, announced on February 7 as...more

Health Care Policy Newsletter - May 2018 pt 2

Foley & Lardner LLP on 5/21/2018

Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly Health Care Newsletter” in which we compile the latest health care policy news and legislation.*Please note that we...more

Trump Administration Drug Pricing Blueprint: Overview and Analysis

Akin Gump Strauss Hauer & Feld LLP on 5/17/2018

• The administration’s drug pricing Blueprint combines proposals that are already under way with new initiatives that may or may not be adopted. • Many of the more dramatic proposals would require federal rulemaking or...more

President Trump Delivers Much Anticipated Drug Pricing Speech

Mintz - Health Care Viewpoints on 5/14/2018

On Friday, after weeks of delay, the President finally delivered his Drug Pricing Speech and released the HHS Blueprint detailing the Trump Administration’s plan to lower drug prices and reduce out-of-pocket costs....more

Health Care Policy Newsletter

Foley & Lardner LLP on 5/14/2018

Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our second “Public Policy Weekly* Health Care Newsletter” in which we compile the latest health care policy news and legislation. Please...more

White House Unveils Proposal on Drug Pricing

Holland & Knight LLP on 2/13/2018

On Feb. 9, 2018, the Trump Administration released a 30-page report analyzing domestic and global factors influencing drug pricing. The report by the Council of Economic Advisers (CEA) is expected to inform the HHS' Fiscal...more

Azar’s Nomination Hearing Highlights Medicare Negotiation of Part B Drug Prices

Mintz - Health Care Viewpoints on 1/11/2018

On January 9th, the Senate Committee on Finance conducted its nomination hearing of Alex Michael Azar II, President Trump’s nominee for Secretary of Health and Human Services. Under President George W. Bush, Mr. Azar served...more

Window on Washington - Vol. 2, Issue 1

Clark Hill PLC on 1/9/2018

Another short-term continuing resolution is all but guaranteed as the current continuing resolution will expire later this month and budget talks last week did not result in a deal or hint at one in the near future. As the...more

Medicaid › Section 340B › Trump Administration

"My best business intelligence, in one easy email…"